Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04569032 · ClinicalTrials.gov registry record · Phase 2
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
A Phase 2 study of Peripheral T-Cell Lymphoma, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 82
- Enrollment target
- 20
- Study locations
NCT04569032 is a Phase 2 study of Peripheral T-Cell Lymphoma that has completed, run by Seagen, a wholly owned subsidiary of Pfizer. The registered enrollment target is 82 participants, below the 104-participant average among 34 other Peripheral T-Cell Lymphoma trials with a reported enrollment target (21% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT04569032, a Phase 2 study of Peripheral T-Cell Lymphoma, has completed, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 82 participants
- Enrollment target
- 20
- Study locations
Study Summary
This clinical trial will study brentuximab vedotin with CHP to find out if the drugs work for people who have certain types of peripheral T-cell lymphoma (PTCL). It will also find out what side effects occur when brentuximab vedotin and CHP are used together. A side effect is anything the drugs do besides treating cancer. CHP is a type of chemotherapy that uses three drugs (cyclophosphamide, doxorubicin, and prednisone). CHP is approved by the FDA to treat certain types of PTCL.
Conditions Studied
Interventions
- DRUG prednisone
- DRUG cyclophosphamide
- DRUG doxorubicin
- DRUG brentuximab vedotin
Study Locations (20)
Colorado
- Rocky Mountain Cancer centers, LLP - Aurora
- Rocky Mountain Cancer centers, LLP - Boulder
- Rocky Mountain Cancer centers, LLP - Colorado Springs
- Rocky Mountain Cancer centers, LLP - Denver
- Rocky Mountain Cancer centers, LLP - Denver
- Rocky Mountain Cancer centers, LLP - Lakewood
- Rocky Mountain Cancer centers, LLP - Littleton
- Rocky Mountain Cancer centers, LLP - Lone Tree
- Rocky Mountain Cancer centers, LLP - Longmont
- Rocky Mountain Cancer centers, LLP - Pueblo
- Rocky Mountain Cancer centers, LLP - Thornton
Alabama
- University of Alabama at Birmingham - Birmingham
- University of Alabama at Birmingham - Birmingham
California
- Stanford Cancer Center - Stanford
- Stanford Hospital and Clinics, Investigational Drug Services - Stanford
Louisiana
- Tulane Cancer Center - New Orleans
- Tulane Medical Center - New Orleans
New York
- Memorial Sloan Kettering Cancer Center David H. Koch Center for Cancer Care - New York
- Memorial Sloan Kettering Cancer Center - New York
Ohio
- Cleveland Clinic taussig Cancer Center Investigational Pharmacy - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2020-11-12 |
| Est. Completion | 2026-01-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04569032
The ClinicalTrials.gov registry entry for NCT04569032 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 104-participant average among 34 other Peripheral T-Cell Lymphoma trials with a reported enrollment target (21% lower). The listed sponsor is Seagen, a wholly owned subsidiary of Pfizer, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Peripheral T-Cell Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which prednisone is the first listed.
NCT04569032 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Colorado, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT04569032 about?
NCT04569032 is a clinical study titled "A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression". This clinical trial will study brentuximab vedotin with CHP to find out if the drugs work for people who have certain types of peripheral T-cell lymphoma (PTCL). It will also find out what side effects occur when brentuximab vedotin and CHP are used together. A side effect is anything the drugs do b...
What is the current status of trial NCT04569032?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2020-11-12. Estimated completion is 2026-01-12.
What conditions does trial NCT04569032 study?
This clinical trial studies the following conditions: Peripheral T-Cell Lymphoma.
What interventions are being tested in trial NCT04569032?
The interventions under investigation include: prednisone (DRUG), cyclophosphamide (DRUG), doxorubicin (DRUG), brentuximab vedotin (DRUG).
Who is sponsoring clinical trial NCT04569032?
This trial is sponsored by Seagen, a wholly owned subsidiary of Pfizer, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04569032 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Louisiana, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral T-Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study
RECRUITING · Phase 2
-
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
RECRUITING · Phase 2
-
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
RECRUITING · Phase 2
-
Amping up With PemJAK
RECRUITING · Phase 2
-
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.